Description of Medical ServiceThe Indigenous Medication Review Service (IMeRSe) study is a collaborative partnership between The Pharmacy Guild of Australia, Griffith University and The National Aboriginal Community Controlled Health Organisation.
The IMeRSe Feasibility Study developed and assessed the feasibility of a culturally responsive Indigenous Medication Review service, delivered by community pharmacists integrated with local Aboriginal Health Services (AHSs).
Description of Medical ConditionThe IMeRSe Feasibility Study recruited clients of AHS who were:
- Aged 18 years and above,
- Living in the community with at least one chronic condition,
- At risk of medication-related problems (as identified by any treating health professional, family member or self-identified) including but not limited to:
– being diagnosed with at least one chronic condition and/or is pregnant and /or is within 2 years post-partum;
– instability of health status and/or medication therapy;
– using high-risk medication(s);
– likelihood of compromised adherence;
– new therapeutic goals;
– potentially incomplete understanding of medication use; or
– failure to respond to treatment in an expected way.
- Who had engaged with the AHS at least 3 times in the past 2 years, and
- Accessed medications from one of the associated community pharmacists.
Reason for applicationThe Sixth Community Pharmacy Agreement provided funding to support a Pharmacy Trial Program (PTP), which seeks to improve clinical outcomes for patients and/or utilise the full scope of a pharmacist’s role in delivering primary health care services.
The outcomes of all PTP Trials will undergo an independent health technology assessment to determine the effectiveness and cost-effectiveness of the trial intervention and inform decisions about any broader rollout. A decision to fund any future programs would be a matter for Government.
Information on the PTP is available on the Department of Health’s website.
Medical Service TypeTherapeutic technology.
Previous Application NumberNot applicable
Supplemental Report Executive SummarySupplemental Report Executive Summary (PDF 343 KB)
Supplemental Report Executive Summary (Word 50 KB)
Consultation SurveyConsultation Survey (PDF 772 KB)
Consultation Survey (Word 77 KB)
MSAC welcomes public consultation input as per the IPAC Public Summary above.
Please send feedback on this application to commentsMSAC@health.gov.au (and cc: email@example.com) including the MSAC application number 1679 in the subject heading of your email.
MSAC consultation input must be received by no later than Friday, 11 February 2022 for it to be considered by MSAC at its March/April 2022 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process